TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Milestone Pharmaceuticals
Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025

Milestone Pharmaceuticals presented clinical trial data for etripamil nasal spray, showing consistent efficacy and safety in treating paroxysmal supraventricular tachycardia (PSVT) across multiple studies, with a New Drug Application currently under FDA review.

Insights
PFE   positive

Demonstrated strong innovation with COVID-19 vaccine and antiviral treatment, maintaining leadership in vaccines and infectious disease research


MIST   positive

Presented promising clinical trial results demonstrating consistent efficacy and safety of their lead investigational product, with a pending FDA New Drug Application and potential for a new treatment option in cardiovascular medicine